Matthew Galsky on Adjuvant Nivolumab Trials

(2:18)

Galsky: Adjuvant Chemo vs. Observation in Bladder Cancer

(2:34)

Effectiveness of adjuvant chemotherapy on patients with bladder cancer

(5:34)

CheckMate 274: adjuvant nivolumab versus placebo for urothelial carcinoma

(1:35)

Matthew Galsky, MD, on the CheckMate-274 study in high risk, muscle-invasive urothelial carcinoma

(2:36)

What are Neoadjuvant and Adjuvant Chemotherapy for Bladder Cancer?

(10:32)

Dr. Matthew Galsky on a Post-Treatment Nomogram in Urothelial Cancer

(1:59)

Matthew Galsky, MD, elaborates on outcomes from the CheckMate 274 trial

(2:53)

Matthew Galsky Gives an Overview of Bladder Cancer

(1:35)

Neoadjuvant and Adjuvant Chemotherapy | Part I: Basics \u0026 Intro for Chemo

(14:17)

Dr. Galsky on Progression on Immunotherapy in Bladder Cancer

(59)

Adjuvant nivolumab as SOC for high-risk muscle-invasive urothelial carcinoma after radical resection

(2:13)

Dr. O’Neil on Adjuvant Therapy in Bladder Cancer

(1:1econd)

Question and Answer about Neoadjuvant and Adjuvant Chemotherapy for Bladder Cancer

(6:8)

Neoadjuvant and Adjuvant Chemotherapy in Bladder Cancer

(20:29)

Adjuvant Chemotherapy Benefit Observed in Patients With Advanced Bladder Cancer

(1:18)

Dr. Galsky Discusses Neoadjuvant Immunotherapy in Bladder Cancer

(1:36)

Single-agent atezolizumab supported for some cisplatin-ineligible mUC patients | Matthew Galsky

(6:13)

Dr. Galsky on Neoadjuvant Immune Checkpoint Blockade in Bladder Cancer

(1:35)

Drs. Kamat, Galsky, \u0026 Baack talk the latest in #BladderCancer from #AUA22

(1:26:34)